Acumen Pharmaceuticals, Inc.
ABOS
$2.41
$0.010.42%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -20.74M | -25.14M | -26.45M | -40.95M | -28.80M |
| Total Depreciation and Amortization | 46.00K | 45.00K | 47.00K | 47.00K | 45.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.30M | 3.00M | 2.94M | 2.80M | 1.99M |
| Change in Net Operating Assets | -5.74M | 2.99M | -7.03M | 6.28M | -7.36M |
| Cash from Operations | -24.13M | -19.10M | -30.49M | -31.83M | -34.12M |
| Capital Expenditure | -- | 0.00 | 0.00 | -9.00K | -79.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -13.81M | 26.25M | 40.51M | 38.49M | 28.77M |
| Cash from Investing | -13.81M | 26.25M | 40.51M | 38.48M | 28.69M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 145.00K | 2.00K | 0.00 | 0.00 | 37.00K |
| Repurchase of Common Stock | -149.00K | 0.00 | 0.00 | 0.00 | -73.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 35.75M | -- | -- | -- | -- |
| Cash from Financing | 35.74M | 2.00K | 0.00 | 0.00 | -36.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2.19M | 7.16M | 10.02M | 6.65M | -5.47M |